Profil
Alan Tyndall is the founder of Magenta Therapeutics, Inc. (2015).
He is currently a Professor-Emeritus at the University of Basel (since 1991) and serves as Secretary at the World Scleroderma Foundation.
Mr. Tyndall received his undergraduate degree from the University of Sydney in 1972.
Mr. Tyndall is also the founder of Iterata AG.
Aktive Positionen von Alan Tyndall
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Basel | Corporate Officer/Principal | 01.01.1991 |
| World Scleroderma Foundation | Unternehmenssekretär | - |
| Iterata AG | Gründer | - |
Ehemalige bekannte Positionen von Alan Tyndall
| Unternehmen | Position | Ende |
|---|---|---|
| MAGENTA THERAPEUTICS | Gründer | - |
Ausbildung von Alan Tyndall
| The University of Sydney | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
| World Scleroderma Foundation | |
| Iterata AG |
